AltruBio Announces Enrollment of First Patient in Phase 2 Clinical Program of ALTB-268 for the Treatment of Ulcerative Colitis
December 07, 2023 08:00 ET
|
AltruBio Inc.
SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBio Announces FDA Clearance of IND Application for Immune Checkpoint Enhancer ALTB-268 to initiate a Phase 2 Clinical Trial for the Treatment of Ulcerative Colitis
September 26, 2023 08:00 ET
|
AltruBio Inc.
SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment...
AltruBio Announces Positive Topline Data from Phase 1 Trial of Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis
August 01, 2023 08:00 ET
|
AltruBio Inc.
ALTB-268 was well tolerated with no serious adverse events across all subject cohorts ALTB-268 demonstrated substantially greater biological activity than first ICE molecule, ALTB-168, enabling...
AltruBio to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting
June 15, 2023 08:03 ET
|
AltruBio Inc.
SAN FRANCISCO, June 15, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBio to Present at the 2023 BIO International Convention
May 31, 2023 08:00 ET
|
AltruBio Inc.
SAN FRANCISCO, May 31, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBio Announces Poster Presentation at Digestive Disease Week Conference 2023
May 08, 2023 08:00 ET
|
AltruBio Inc.
SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBio Announces Panels and Presentations at Three March Healthcare Conferences
March 09, 2023 08:00 ET
|
AltruBio Inc.
SAN FRANCISCO, March 09, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment...
AltruBio Announces First Patient Dosed in Phase 1 Trial of Next-Generation Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis
January 23, 2023 09:00 ET
|
AltruBio Inc.
SAN FRANCISCO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBio Announces Poster Presentation on Immune Checkpoint Enhancer, ALTB-168 at Crohn’s & Colitis Congress 2023
January 19, 2023 11:00 ET
|
AltruBio Inc.
SAN FRANCISCO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBio to Present at Biotech Showcase™ 2023
January 05, 2023 08:00 ET
|
AltruBio Inc.
SAN FRANCISCO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...